Mind Medicine (MindMed) Inc.
Mind Medicine (MindMed) Inc. (MMED.NE) Stock Competitors & Peer Comparison
See (MMED.NE) competitors and their performances in Stock Market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| MMED.NE | CA$14.90 | +9.48% | 1.1B | -4.50 | -CA$3.31 | N/A |
| BLU.TO | CA$19.48 | -0.10% | 2.5B | -20.29 | -CA$0.96 | N/A |
| DRUG.CN | CA$58.56 | -2.43% | 414.8M | -42.74 | -CA$1.37 | N/A |
| FRX.TO | CA$11.94 | +4.28% | 328.1M | -19.26 | -CA$0.62 | N/A |
| EPRX.TO | CA$7.33 | +1.81% | 262.6M | -6.16 | -CA$1.19 | N/A |
| CYBN.NE | CA$9.76 | +1.67% | 226.8M | -1.60 | -CA$6.15 | N/A |
| ONC.TO | CA$1.42 | +2.16% | 142.3M | -3.84 | -CA$0.37 | N/A |
| MSCL.TO | CA$0.59 | +1.72% | 103.9M | 2.27 | CA$0.26 | N/A |
| HBP.TO | CA$1.35 | +0.00% | 100.1M | -1.31 | -CA$1.03 | N/A |
| MDNA.TO | CA$1.10 | -1.79% | 75.6M | -6.87 | -CA$0.16 | N/A |
Stock Comparison
MMED.NE vs BLU.TO Comparison August 2025
MMED.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED.NE stands at 1.1B. In comparison, BLU.TO has a market cap of 2.5B. Regarding current trading prices, MMED.NE is priced at CA$14.90, while BLU.TO trades at CA$19.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED.NE currently has a P/E ratio of -4.50, whereas BLU.TO's P/E ratio is -20.29. In terms of profitability, MMED.NE's ROE is -0.50%, compared to BLU.TO's ROE of -0.22%. Regarding short-term risk, MMED.NE is more volatile compared to BLU.TO. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.NE.Check BLU.TO's competition here
MMED.NE vs DRUG.CN Comparison August 2025
MMED.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED.NE stands at 1.1B. In comparison, DRUG.CN has a market cap of 414.8M. Regarding current trading prices, MMED.NE is priced at CA$14.90, while DRUG.CN trades at CA$58.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED.NE currently has a P/E ratio of -4.50, whereas DRUG.CN's P/E ratio is -42.74. In terms of profitability, MMED.NE's ROE is -0.50%, compared to DRUG.CN's ROE of -0.11%. Regarding short-term risk, MMED.NE is more volatile compared to DRUG.CN. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.NE.Check DRUG.CN's competition here
MMED.NE vs FRX.TO Comparison August 2025
MMED.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED.NE stands at 1.1B. In comparison, FRX.TO has a market cap of 328.1M. Regarding current trading prices, MMED.NE is priced at CA$14.90, while FRX.TO trades at CA$11.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED.NE currently has a P/E ratio of -4.50, whereas FRX.TO's P/E ratio is -19.26. In terms of profitability, MMED.NE's ROE is -0.50%, compared to FRX.TO's ROE of +6.15%. Regarding short-term risk, MMED.NE is more volatile compared to FRX.TO. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.NE.Check FRX.TO's competition here
MMED.NE vs EPRX.TO Comparison August 2025
MMED.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED.NE stands at 1.1B. In comparison, EPRX.TO has a market cap of 262.6M. Regarding current trading prices, MMED.NE is priced at CA$14.90, while EPRX.TO trades at CA$7.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED.NE currently has a P/E ratio of -4.50, whereas EPRX.TO's P/E ratio is -6.16. In terms of profitability, MMED.NE's ROE is -0.50%, compared to EPRX.TO's ROE of -1.19%. Regarding short-term risk, MMED.NE is more volatile compared to EPRX.TO. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.NE.Check EPRX.TO's competition here
MMED.NE vs CYBN.NE Comparison August 2025
MMED.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED.NE stands at 1.1B. In comparison, CYBN.NE has a market cap of 226.8M. Regarding current trading prices, MMED.NE is priced at CA$14.90, while CYBN.NE trades at CA$9.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED.NE currently has a P/E ratio of -4.50, whereas CYBN.NE's P/E ratio is -1.60. In terms of profitability, MMED.NE's ROE is -0.50%, compared to CYBN.NE's ROE of -0.39%. Regarding short-term risk, MMED.NE is more volatile compared to CYBN.NE. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.NE.Check CYBN.NE's competition here
MMED.NE vs ONC.TO Comparison August 2025
MMED.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED.NE stands at 1.1B. In comparison, ONC.TO has a market cap of 142.3M. Regarding current trading prices, MMED.NE is priced at CA$14.90, while ONC.TO trades at CA$1.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED.NE currently has a P/E ratio of -4.50, whereas ONC.TO's P/E ratio is -3.84. In terms of profitability, MMED.NE's ROE is -0.50%, compared to ONC.TO's ROE of -4.40%. Regarding short-term risk, MMED.NE is more volatile compared to ONC.TO. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.NE.Check ONC.TO's competition here
MMED.NE vs MSCL.TO Comparison August 2025
MMED.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED.NE stands at 1.1B. In comparison, MSCL.TO has a market cap of 103.9M. Regarding current trading prices, MMED.NE is priced at CA$14.90, while MSCL.TO trades at CA$0.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED.NE currently has a P/E ratio of -4.50, whereas MSCL.TO's P/E ratio is 2.27. In terms of profitability, MMED.NE's ROE is -0.50%, compared to MSCL.TO's ROE of -0.69%. Regarding short-term risk, MMED.NE is more volatile compared to MSCL.TO. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.NE.Check MSCL.TO's competition here
MMED.NE vs HBP.TO Comparison August 2025
MMED.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED.NE stands at 1.1B. In comparison, HBP.TO has a market cap of 100.1M. Regarding current trading prices, MMED.NE is priced at CA$14.90, while HBP.TO trades at CA$1.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED.NE currently has a P/E ratio of -4.50, whereas HBP.TO's P/E ratio is -1.31. In terms of profitability, MMED.NE's ROE is -0.50%, compared to HBP.TO's ROE of +13.32%. Regarding short-term risk, MMED.NE is more volatile compared to HBP.TO. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.NE.Check HBP.TO's competition here
MMED.NE vs MDNA.TO Comparison August 2025
MMED.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED.NE stands at 1.1B. In comparison, MDNA.TO has a market cap of 75.6M. Regarding current trading prices, MMED.NE is priced at CA$14.90, while MDNA.TO trades at CA$1.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED.NE currently has a P/E ratio of -4.50, whereas MDNA.TO's P/E ratio is -6.87. In terms of profitability, MMED.NE's ROE is -0.50%, compared to MDNA.TO's ROE of -0.74%. Regarding short-term risk, MMED.NE is more volatile compared to MDNA.TO. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.NE.Check MDNA.TO's competition here
MMED.NE vs MSET.CN Comparison August 2025
MMED.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED.NE stands at 1.1B. In comparison, MSET.CN has a market cap of 75M. Regarding current trading prices, MMED.NE is priced at CA$14.90, while MSET.CN trades at CA$0.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED.NE currently has a P/E ratio of -4.50, whereas MSET.CN's P/E ratio is -12.33. In terms of profitability, MMED.NE's ROE is -0.50%, compared to MSET.CN's ROE of -3.17%. Regarding short-term risk, Volatility data is not available for a full comparison. MMED.NE has daily volatility of 26.02 and MSET.CN has daily volatility of N/A.Check MSET.CN's competition here
MMED.NE vs ONCO.CN Comparison August 2025
MMED.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED.NE stands at 1.1B. In comparison, ONCO.CN has a market cap of 63.8M. Regarding current trading prices, MMED.NE is priced at CA$14.90, while ONCO.CN trades at CA$1.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED.NE currently has a P/E ratio of -4.50, whereas ONCO.CN's P/E ratio is -147.00. In terms of profitability, MMED.NE's ROE is -0.50%, compared to ONCO.CN's ROE of -3.52%. Regarding short-term risk, MMED.NE is more volatile compared to ONCO.CN. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.NE.Check ONCO.CN's competition here
MMED.NE vs SVA.TO Comparison August 2025
MMED.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED.NE stands at 1.1B. In comparison, SVA.TO has a market cap of 59.1M. Regarding current trading prices, MMED.NE is priced at CA$14.90, while SVA.TO trades at CA$0.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED.NE currently has a P/E ratio of -4.50, whereas SVA.TO's P/E ratio is -2.57. In terms of profitability, MMED.NE's ROE is -0.50%, compared to SVA.TO's ROE of +1.37%. Regarding short-term risk, MMED.NE is more volatile compared to SVA.TO. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.NE.Check SVA.TO's competition here
MMED.NE vs PMN.TO Comparison August 2025
MMED.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED.NE stands at 1.1B. In comparison, PMN.TO has a market cap of 51.5M. Regarding current trading prices, MMED.NE is priced at CA$14.90, while PMN.TO trades at CA$6.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED.NE currently has a P/E ratio of -4.50, whereas PMN.TO's P/E ratio is -1.78. In terms of profitability, MMED.NE's ROE is -0.50%, compared to PMN.TO's ROE of -5.57%. Regarding short-term risk, MMED.NE is more volatile compared to PMN.TO. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.NE.Check PMN.TO's competition here
MMED.NE vs GLAB.CN Comparison August 2025
MMED.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED.NE stands at 1.1B. In comparison, GLAB.CN has a market cap of 45.9M. Regarding current trading prices, MMED.NE is priced at CA$14.90, while GLAB.CN trades at CA$0.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED.NE currently has a P/E ratio of -4.50, whereas GLAB.CN's P/E ratio is -10.00. In terms of profitability, MMED.NE's ROE is -0.50%, compared to GLAB.CN's ROE of +1.07%. Regarding short-term risk, MMED.NE is more volatile compared to GLAB.CN. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.NE.Check GLAB.CN's competition here
MMED.NE vs IGX.TO Comparison August 2025
MMED.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED.NE stands at 1.1B. In comparison, IGX.TO has a market cap of 41.9M. Regarding current trading prices, MMED.NE is priced at CA$14.90, while IGX.TO trades at CA$0.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED.NE currently has a P/E ratio of -4.50, whereas IGX.TO's P/E ratio is -3.00. In terms of profitability, MMED.NE's ROE is -0.50%, compared to IGX.TO's ROE of +1.27%. Regarding short-term risk, MMED.NE is more volatile compared to IGX.TO. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.NE.Check IGX.TO's competition here
MMED.NE vs PHRM.CN Comparison August 2025
MMED.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED.NE stands at 1.1B. In comparison, PHRM.CN has a market cap of 34.1M. Regarding current trading prices, MMED.NE is priced at CA$14.90, while PHRM.CN trades at CA$0.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED.NE currently has a P/E ratio of -4.50, whereas PHRM.CN's P/E ratio is -7.70. In terms of profitability, MMED.NE's ROE is -0.50%, compared to PHRM.CN's ROE of -0.83%. Regarding short-term risk, MMED.NE is more volatile compared to PHRM.CN. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.NE.Check PHRM.CN's competition here
MMED.NE vs DTC.CN Comparison August 2025
MMED.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED.NE stands at 1.1B. In comparison, DTC.CN has a market cap of 32.8M. Regarding current trading prices, MMED.NE is priced at CA$14.90, while DTC.CN trades at CA$0.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED.NE currently has a P/E ratio of -4.50, whereas DTC.CN's P/E ratio is -7.50. In terms of profitability, MMED.NE's ROE is -0.50%, compared to DTC.CN's ROE of +1.30%. Regarding short-term risk, MMED.NE is more volatile compared to DTC.CN. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.NE.Check DTC.CN's competition here
MMED.NE vs MBX.TO Comparison August 2025
MMED.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED.NE stands at 1.1B. In comparison, MBX.TO has a market cap of 32.2M. Regarding current trading prices, MMED.NE is priced at CA$14.90, while MBX.TO trades at CA$0.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED.NE currently has a P/E ratio of -4.50, whereas MBX.TO's P/E ratio is 23.00. In terms of profitability, MMED.NE's ROE is -0.50%, compared to MBX.TO's ROE of +0.05%. Regarding short-term risk, MMED.NE is more volatile compared to MBX.TO. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.NE.Check MBX.TO's competition here
MMED.NE vs RVX.TO Comparison August 2025
MMED.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED.NE stands at 1.1B. In comparison, RVX.TO has a market cap of 27M. Regarding current trading prices, MMED.NE is priced at CA$14.90, while RVX.TO trades at CA$0.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED.NE currently has a P/E ratio of -4.50, whereas RVX.TO's P/E ratio is -9.50. In terms of profitability, MMED.NE's ROE is -0.50%, compared to RVX.TO's ROE of +0.06%. Regarding short-term risk, MMED.NE is more volatile compared to RVX.TO. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.NE.Check RVX.TO's competition here
MMED.NE vs AEZS.TO Comparison August 2025
MMED.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED.NE stands at 1.1B. In comparison, AEZS.TO has a market cap of 25.4M. Regarding current trading prices, MMED.NE is priced at CA$14.90, while AEZS.TO trades at CA$8.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED.NE currently has a P/E ratio of -4.50, whereas AEZS.TO's P/E ratio is -2.61. In terms of profitability, MMED.NE's ROE is -0.50%, compared to AEZS.TO's ROE of -0.14%. Regarding short-term risk, MMED.NE is more volatile compared to AEZS.TO. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.NE.Check AEZS.TO's competition here
MMED.NE vs DOSE.CN Comparison August 2025
MMED.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED.NE stands at 1.1B. In comparison, DOSE.CN has a market cap of 24M. Regarding current trading prices, MMED.NE is priced at CA$14.90, while DOSE.CN trades at CA$0.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED.NE currently has a P/E ratio of -4.50, whereas DOSE.CN's P/E ratio is -4.62. In terms of profitability, MMED.NE's ROE is -0.50%, compared to DOSE.CN's ROE of +1.06%. Regarding short-term risk, MMED.NE is more volatile compared to DOSE.CN. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.NE.Check DOSE.CN's competition here
MMED.NE vs PREV.CN Comparison August 2025
MMED.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED.NE stands at 1.1B. In comparison, PREV.CN has a market cap of 20M. Regarding current trading prices, MMED.NE is priced at CA$14.90, while PREV.CN trades at CA$0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED.NE currently has a P/E ratio of -4.50, whereas PREV.CN's P/E ratio is -35.00. In terms of profitability, MMED.NE's ROE is -0.50%, compared to PREV.CN's ROE of +0.26%. Regarding short-term risk, MMED.NE is more volatile compared to PREV.CN. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.NE.Check PREV.CN's competition here
MMED.NE vs TELI.CN Comparison August 2025
MMED.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED.NE stands at 1.1B. In comparison, TELI.CN has a market cap of 17.7M. Regarding current trading prices, MMED.NE is priced at CA$14.90, while TELI.CN trades at CA$0.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED.NE currently has a P/E ratio of -4.50, whereas TELI.CN's P/E ratio is -8.25. In terms of profitability, MMED.NE's ROE is -0.50%, compared to TELI.CN's ROE of -2.08%. Regarding short-term risk, MMED.NE is more volatile compared to TELI.CN. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.NE.Check TELI.CN's competition here
MMED.NE vs BCT.TO Comparison August 2025
MMED.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED.NE stands at 1.1B. In comparison, BCT.TO has a market cap of 16.7M. Regarding current trading prices, MMED.NE is priced at CA$14.90, while BCT.TO trades at CA$0.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED.NE currently has a P/E ratio of -4.50, whereas BCT.TO's P/E ratio is -0.09. In terms of profitability, MMED.NE's ROE is -0.50%, compared to BCT.TO's ROE of -4.40%. Regarding short-term risk, MMED.NE is more volatile compared to BCT.TO. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.NE.Check BCT.TO's competition here
MMED.NE vs REUN.TO Comparison August 2025
MMED.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED.NE stands at 1.1B. In comparison, REUN.TO has a market cap of 16.6M. Regarding current trading prices, MMED.NE is priced at CA$14.90, while REUN.TO trades at CA$1.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED.NE currently has a P/E ratio of -4.50, whereas REUN.TO's P/E ratio is -0.43. In terms of profitability, MMED.NE's ROE is -0.50%, compared to REUN.TO's ROE of -1.10%. Regarding short-term risk, MMED.NE is more volatile compared to REUN.TO. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.NE.Check REUN.TO's competition here
MMED.NE vs MDMA.CN Comparison August 2025
MMED.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED.NE stands at 1.1B. In comparison, MDMA.CN has a market cap of 13.7M. Regarding current trading prices, MMED.NE is priced at CA$14.90, while MDMA.CN trades at CA$0.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED.NE currently has a P/E ratio of -4.50, whereas MDMA.CN's P/E ratio is -6.50. In terms of profitability, MMED.NE's ROE is -0.50%, compared to MDMA.CN's ROE of -0.84%. Regarding short-term risk, MMED.NE is more volatile compared to MDMA.CN. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.NE.Check MDMA.CN's competition here
MMED.NE vs IMV.TO Comparison August 2025
MMED.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED.NE stands at 1.1B. In comparison, IMV.TO has a market cap of 13.1M. Regarding current trading prices, MMED.NE is priced at CA$14.90, while IMV.TO trades at CA$1.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED.NE currently has a P/E ratio of -4.50, whereas IMV.TO's P/E ratio is -0.18. In terms of profitability, MMED.NE's ROE is -0.50%, compared to IMV.TO's ROE of -4.95%. Regarding short-term risk, MMED.NE is more volatile compared to IMV.TO. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.NE.Check IMV.TO's competition here
MMED.NE vs BETR.CN Comparison August 2025
MMED.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED.NE stands at 1.1B. In comparison, BETR.CN has a market cap of 12.9M. Regarding current trading prices, MMED.NE is priced at CA$14.90, while BETR.CN trades at CA$0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED.NE currently has a P/E ratio of -4.50, whereas BETR.CN's P/E ratio is -8.50. In terms of profitability, MMED.NE's ROE is -0.50%, compared to BETR.CN's ROE of +0.31%. Regarding short-term risk, MMED.NE is more volatile compared to BETR.CN. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.NE.Check BETR.CN's competition here
MMED.NE vs BLAB.CN Comparison August 2025
MMED.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED.NE stands at 1.1B. In comparison, BLAB.CN has a market cap of 11.4M. Regarding current trading prices, MMED.NE is priced at CA$14.90, while BLAB.CN trades at CA$0.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED.NE currently has a P/E ratio of -4.50, whereas BLAB.CN's P/E ratio is -2.33. In terms of profitability, MMED.NE's ROE is -0.50%, compared to BLAB.CN's ROE of +2.71%. Regarding short-term risk, MMED.NE is more volatile compared to BLAB.CN. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.NE.Check BLAB.CN's competition here
MMED.NE vs GLOW.CN Comparison August 2025
MMED.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED.NE stands at 1.1B. In comparison, GLOW.CN has a market cap of 11.1M. Regarding current trading prices, MMED.NE is priced at CA$14.90, while GLOW.CN trades at CA$0.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED.NE currently has a P/E ratio of -4.50, whereas GLOW.CN's P/E ratio is -2.17. In terms of profitability, MMED.NE's ROE is -0.50%, compared to GLOW.CN's ROE of +296.19%. Regarding short-term risk, MMED.NE is more volatile compared to GLOW.CN. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.NE.Check GLOW.CN's competition here
MMED.NE vs TBP.TO Comparison August 2025
MMED.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED.NE stands at 1.1B. In comparison, TBP.TO has a market cap of 10.6M. Regarding current trading prices, MMED.NE is priced at CA$14.90, while TBP.TO trades at CA$0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED.NE currently has a P/E ratio of -4.50, whereas TBP.TO's P/E ratio is -0.31. In terms of profitability, MMED.NE's ROE is -0.50%, compared to TBP.TO's ROE of -4.68%. Regarding short-term risk, MMED.NE is more volatile compared to TBP.TO. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.NE.Check TBP.TO's competition here
MMED.NE vs BIOV.CN Comparison August 2025
MMED.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED.NE stands at 1.1B. In comparison, BIOV.CN has a market cap of 10.2M. Regarding current trading prices, MMED.NE is priced at CA$14.90, while BIOV.CN trades at CA$0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED.NE currently has a P/E ratio of -4.50, whereas BIOV.CN's P/E ratio is -1.75. In terms of profitability, MMED.NE's ROE is -0.50%, compared to BIOV.CN's ROE of +3.80%. Regarding short-term risk, MMED.NE is more volatile compared to BIOV.CN. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.NE.Check BIOV.CN's competition here
MMED.NE vs MCUR.CN Comparison August 2025
MMED.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED.NE stands at 1.1B. In comparison, MCUR.CN has a market cap of 7M. Regarding current trading prices, MMED.NE is priced at CA$14.90, while MCUR.CN trades at CA$0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED.NE currently has a P/E ratio of -4.50, whereas MCUR.CN's P/E ratio is -0.75. In terms of profitability, MMED.NE's ROE is -0.50%, compared to MCUR.CN's ROE of -1.61%. Regarding short-term risk, MMED.NE is more volatile compared to MCUR.CN. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.NE.Check MCUR.CN's competition here
MMED.NE vs COOL.CN Comparison August 2025
MMED.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED.NE stands at 1.1B. In comparison, COOL.CN has a market cap of 6.8M. Regarding current trading prices, MMED.NE is priced at CA$14.90, while COOL.CN trades at CA$0.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED.NE currently has a P/E ratio of -4.50, whereas COOL.CN's P/E ratio is -1.32. In terms of profitability, MMED.NE's ROE is -0.50%, compared to COOL.CN's ROE of -2.90%. Regarding short-term risk, MMED.NE is more volatile compared to COOL.CN. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.NE.Check COOL.CN's competition here
MMED.NE vs TRYP.CN Comparison August 2025
MMED.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED.NE stands at 1.1B. In comparison, TRYP.CN has a market cap of 5.8M. Regarding current trading prices, MMED.NE is priced at CA$14.90, while TRYP.CN trades at CA$0.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED.NE currently has a P/E ratio of -4.50, whereas TRYP.CN's P/E ratio is -1.50. In terms of profitability, MMED.NE's ROE is -0.50%, compared to TRYP.CN's ROE of +4.03%. Regarding short-term risk, MMED.NE is more volatile compared to TRYP.CN. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.NE.Check TRYP.CN's competition here
MMED.NE vs ASEP.CN Comparison August 2025
MMED.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED.NE stands at 1.1B. In comparison, ASEP.CN has a market cap of 5.6M. Regarding current trading prices, MMED.NE is priced at CA$14.90, while ASEP.CN trades at CA$0.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED.NE currently has a P/E ratio of -4.50, whereas ASEP.CN's P/E ratio is -0.83. In terms of profitability, MMED.NE's ROE is -0.50%, compared to ASEP.CN's ROE of -0.23%. Regarding short-term risk, MMED.NE is more volatile compared to ASEP.CN. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.NE.Check ASEP.CN's competition here
MMED.NE vs CMND.CN Comparison August 2025
MMED.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED.NE stands at 1.1B. In comparison, CMND.CN has a market cap of 5.1M. Regarding current trading prices, MMED.NE is priced at CA$14.90, while CMND.CN trades at CA$1.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED.NE currently has a P/E ratio of -4.50, whereas CMND.CN's P/E ratio is -0.04. In terms of profitability, MMED.NE's ROE is -0.50%, compared to CMND.CN's ROE of +44.20%. Regarding short-term risk, MMED.NE is more volatile compared to CMND.CN. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.NE.Check CMND.CN's competition here
MMED.NE vs GTTX.CN Comparison August 2025
MMED.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED.NE stands at 1.1B. In comparison, GTTX.CN has a market cap of 4.6M. Regarding current trading prices, MMED.NE is priced at CA$14.90, while GTTX.CN trades at CA$0.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED.NE currently has a P/E ratio of -4.50, whereas GTTX.CN's P/E ratio is -12.00. In terms of profitability, MMED.NE's ROE is -0.50%, compared to GTTX.CN's ROE of -0.35%. Regarding short-term risk, MMED.NE is more volatile compared to GTTX.CN. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.NE.Check GTTX.CN's competition here
MMED.NE vs APS.TO Comparison August 2025
MMED.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED.NE stands at 1.1B. In comparison, APS.TO has a market cap of 4.4M. Regarding current trading prices, MMED.NE is priced at CA$14.90, while APS.TO trades at CA$1.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED.NE currently has a P/E ratio of -4.50, whereas APS.TO's P/E ratio is -0.16. In terms of profitability, MMED.NE's ROE is -0.50%, compared to APS.TO's ROE of +2.38%. Regarding short-term risk, MMED.NE is more volatile compared to APS.TO. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.NE.Check APS.TO's competition here
MMED.NE vs AWKN.NE Comparison August 2025
MMED.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED.NE stands at 1.1B. In comparison, AWKN.NE has a market cap of 3.9M. Regarding current trading prices, MMED.NE is priced at CA$14.90, while AWKN.NE trades at CA$0.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED.NE currently has a P/E ratio of -4.50, whereas AWKN.NE's P/E ratio is -0.36. In terms of profitability, MMED.NE's ROE is -0.50%, compared to AWKN.NE's ROE of -4.29%. Regarding short-term risk, MMED.NE is more volatile compared to AWKN.NE. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.NE.Check AWKN.NE's competition here
MMED.NE vs MYND.CN Comparison August 2025
MMED.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED.NE stands at 1.1B. In comparison, MYND.CN has a market cap of 3.3M. Regarding current trading prices, MMED.NE is priced at CA$14.90, while MYND.CN trades at CA$0.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED.NE currently has a P/E ratio of -4.50, whereas MYND.CN's P/E ratio is -3.50. In terms of profitability, MMED.NE's ROE is -0.50%, compared to MYND.CN's ROE of +0.11%. Regarding short-term risk, MMED.NE is less volatile compared to MYND.CN. This indicates potentially lower risk in terms of short-term price fluctuations for MMED.NE.Check MYND.CN's competition here
MMED.NE vs IPCI.TO Comparison August 2025
MMED.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED.NE stands at 1.1B. In comparison, IPCI.TO has a market cap of 2.6M. Regarding current trading prices, MMED.NE is priced at CA$14.90, while IPCI.TO trades at CA$0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED.NE currently has a P/E ratio of -4.50, whereas IPCI.TO's P/E ratio is -0.67. In terms of profitability, MMED.NE's ROE is -0.50%, compared to IPCI.TO's ROE of +0.31%. Regarding short-term risk, MMED.NE is more volatile compared to IPCI.TO. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.NE.Check IPCI.TO's competition here
MMED.NE vs MOOD.CN Comparison August 2025
MMED.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED.NE stands at 1.1B. In comparison, MOOD.CN has a market cap of 2.6M. Regarding current trading prices, MMED.NE is priced at CA$14.90, while MOOD.CN trades at CA$0.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED.NE currently has a P/E ratio of -4.50, whereas MOOD.CN's P/E ratio is -9.50. In terms of profitability, MMED.NE's ROE is -0.50%, compared to MOOD.CN's ROE of -0.34%. Regarding short-term risk, MMED.NE is more volatile compared to MOOD.CN. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.NE.Check MOOD.CN's competition here
MMED.NE vs APLI.TO Comparison August 2025
MMED.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED.NE stands at 1.1B. In comparison, APLI.TO has a market cap of 2.4M. Regarding current trading prices, MMED.NE is priced at CA$14.90, while APLI.TO trades at CA$0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED.NE currently has a P/E ratio of -4.50, whereas APLI.TO's P/E ratio is -1.00. In terms of profitability, MMED.NE's ROE is -0.50%, compared to APLI.TO's ROE of +0.20%. Regarding short-term risk, MMED.NE is less volatile compared to APLI.TO. This indicates potentially lower risk in terms of short-term price fluctuations for MMED.NE.Check APLI.TO's competition here
MMED.NE vs AGN.CN Comparison August 2025
MMED.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED.NE stands at 1.1B. In comparison, AGN.CN has a market cap of 2.2M. Regarding current trading prices, MMED.NE is priced at CA$14.90, while AGN.CN trades at CA$0.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED.NE currently has a P/E ratio of -4.50, whereas AGN.CN's P/E ratio is -0.81. In terms of profitability, MMED.NE's ROE is -0.50%, compared to AGN.CN's ROE of -0.99%. Regarding short-term risk, MMED.NE is more volatile compared to AGN.CN. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.NE.Check AGN.CN's competition here
MMED.NE vs BRAX.CN Comparison August 2025
MMED.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED.NE stands at 1.1B. In comparison, BRAX.CN has a market cap of 1.4M. Regarding current trading prices, MMED.NE is priced at CA$14.90, while BRAX.CN trades at CA$0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED.NE currently has a P/E ratio of -4.50, whereas BRAX.CN's P/E ratio is -0.10. In terms of profitability, MMED.NE's ROE is -0.50%, compared to BRAX.CN's ROE of -2.49%. Regarding short-term risk, MMED.NE is more volatile compared to BRAX.CN. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.NE.Check BRAX.CN's competition here
MMED.NE vs ENBI.CN Comparison August 2025
MMED.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED.NE stands at 1.1B. In comparison, ENBI.CN has a market cap of 1.3M. Regarding current trading prices, MMED.NE is priced at CA$14.90, while ENBI.CN trades at CA$0.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED.NE currently has a P/E ratio of -4.50, whereas ENBI.CN's P/E ratio is -3.17. In terms of profitability, MMED.NE's ROE is -0.50%, compared to ENBI.CN's ROE of -1.10%. Regarding short-term risk, MMED.NE is more volatile compared to ENBI.CN. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.NE.Check ENBI.CN's competition here
MMED.NE vs HAVN.CN Comparison August 2025
MMED.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED.NE stands at 1.1B. In comparison, HAVN.CN has a market cap of 1.2M. Regarding current trading prices, MMED.NE is priced at CA$14.90, while HAVN.CN trades at CA$0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED.NE currently has a P/E ratio of -4.50, whereas HAVN.CN's P/E ratio is -0.01. In terms of profitability, MMED.NE's ROE is -0.50%, compared to HAVN.CN's ROE of +0.00%. Regarding short-term risk, MMED.NE is more volatile compared to HAVN.CN. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.NE.Check HAVN.CN's competition here
MMED.NE vs LEXT.CN Comparison August 2025
MMED.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED.NE stands at 1.1B. In comparison, LEXT.CN has a market cap of 1.1M. Regarding current trading prices, MMED.NE is priced at CA$14.90, while LEXT.CN trades at CA$0.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED.NE currently has a P/E ratio of -4.50, whereas LEXT.CN's P/E ratio is -0.50. In terms of profitability, MMED.NE's ROE is -0.50%, compared to LEXT.CN's ROE of -2.39%. Regarding short-term risk, MMED.NE is more volatile compared to LEXT.CN. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.NE.Check LEXT.CN's competition here
MMED.NE vs CHGX.CN Comparison August 2025
MMED.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED.NE stands at 1.1B. In comparison, CHGX.CN has a market cap of 415.6K. Regarding current trading prices, MMED.NE is priced at CA$14.90, while CHGX.CN trades at CA$0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED.NE currently has a P/E ratio of -4.50, whereas CHGX.CN's P/E ratio is -0.50. In terms of profitability, MMED.NE's ROE is -0.50%, compared to CHGX.CN's ROE of +0.16%. Regarding short-term risk, MMED.NE is more volatile compared to CHGX.CN. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.NE.Check CHGX.CN's competition here
MMED.NE vs CURE.CN Comparison August 2025
MMED.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED.NE stands at 1.1B. In comparison, CURE.CN has a market cap of 408K. Regarding current trading prices, MMED.NE is priced at CA$14.90, while CURE.CN trades at CA$0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED.NE currently has a P/E ratio of -4.50, whereas CURE.CN's P/E ratio is 0.17. In terms of profitability, MMED.NE's ROE is -0.50%, compared to CURE.CN's ROE of -0.16%. Regarding short-term risk, MMED.NE is more volatile compared to CURE.CN. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.NE.Check CURE.CN's competition here
MMED.NE vs NIRV.CN Comparison August 2025
MMED.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED.NE stands at 1.1B. In comparison, NIRV.CN has a market cap of 385.9K. Regarding current trading prices, MMED.NE is priced at CA$14.90, while NIRV.CN trades at CA$0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED.NE currently has a P/E ratio of -4.50, whereas NIRV.CN's P/E ratio is -0.40. In terms of profitability, MMED.NE's ROE is -0.50%, compared to NIRV.CN's ROE of +0.00%. Regarding short-term risk, MMED.NE is more volatile compared to NIRV.CN. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.NE.Check NIRV.CN's competition here
MMED.NE vs ABRT.CN Comparison August 2025
MMED.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED.NE stands at 1.1B. In comparison, ABRT.CN has a market cap of 372.1K. Regarding current trading prices, MMED.NE is priced at CA$14.90, while ABRT.CN trades at CA$0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED.NE currently has a P/E ratio of -4.50, whereas ABRT.CN's P/E ratio is -0.10. In terms of profitability, MMED.NE's ROE is -0.50%, compared to ABRT.CN's ROE of +16.27%. Regarding short-term risk, MMED.NE is more volatile compared to ABRT.CN. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.NE.Check ABRT.CN's competition here
MMED.NE vs WBIO.CN Comparison August 2025
MMED.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED.NE stands at 1.1B. In comparison, WBIO.CN has a market cap of 324.8K. Regarding current trading prices, MMED.NE is priced at CA$14.90, while WBIO.CN trades at CA$0.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED.NE currently has a P/E ratio of -4.50, whereas WBIO.CN's P/E ratio is 0.41. In terms of profitability, MMED.NE's ROE is -0.50%, compared to WBIO.CN's ROE of +0.19%. Regarding short-term risk, MMED.NE is more volatile compared to WBIO.CN. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.NE.Check WBIO.CN's competition here
MMED.NE vs NSHS.CN Comparison August 2025
MMED.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED.NE stands at 1.1B. In comparison, NSHS.CN has a market cap of 308.3K. Regarding current trading prices, MMED.NE is priced at CA$14.90, while NSHS.CN trades at CA$0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED.NE currently has a P/E ratio of -4.50, whereas NSHS.CN's P/E ratio is 1.00. In terms of profitability, MMED.NE's ROE is -0.50%, compared to NSHS.CN's ROE of -0.13%. Regarding short-term risk, MMED.NE is more volatile compared to NSHS.CN. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.NE.Check NSHS.CN's competition here
MMED.NE vs NOVA.CN Comparison August 2025
MMED.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED.NE stands at 1.1B. In comparison, NOVA.CN has a market cap of 148.3K. Regarding current trading prices, MMED.NE is priced at CA$14.90, while NOVA.CN trades at CA$0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED.NE currently has a P/E ratio of -4.50, whereas NOVA.CN's P/E ratio is -0.05. In terms of profitability, MMED.NE's ROE is -0.50%, compared to NOVA.CN's ROE of -0.26%. Regarding short-term risk, MMED.NE is more volatile compared to NOVA.CN. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.NE.Check NOVA.CN's competition here
MMED.NE vs IN.TO Comparison August 2025
MMED.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED.NE stands at 1.1B. In comparison, IN.TO has a market cap of 0. Regarding current trading prices, MMED.NE is priced at CA$14.90, while IN.TO trades at CA$4.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED.NE currently has a P/E ratio of -4.50, whereas IN.TO's P/E ratio is -2.77. In terms of profitability, MMED.NE's ROE is -0.50%, compared to IN.TO's ROE of -175.73%. Regarding short-term risk, MMED.NE is more volatile compared to IN.TO. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.NE.Check IN.TO's competition here
MMED.NE vs TRIL.TO Comparison August 2025
MMED.NE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED.NE stands at 1.1B. In comparison, TRIL.TO has a market cap of 0. Regarding current trading prices, MMED.NE is priced at CA$14.90, while TRIL.TO trades at CA$23.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED.NE currently has a P/E ratio of -4.50, whereas TRIL.TO's P/E ratio is -34.06. In terms of profitability, MMED.NE's ROE is -0.50%, compared to TRIL.TO's ROE of -0.43%. Regarding short-term risk, MMED.NE is more volatile compared to TRIL.TO. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.NE.Check TRIL.TO's competition here